Influenza reverse genetics: Dissecting immunity and pathogenesis

Expert Reviews in Molecular Medicine

Volumn 16, Issue , 2014, Pages

  Ye, Siying ^a,b   Evans, Justin G ^a,b   Stambas, John ^a,b  

^a DEAKIN UNIVERSITY   (Australia)

^b CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; INFLUEZA VIRUS VECTOR; LIVE VACCINE; NONSTRUCTURAL PROTEIN 1; PROTEIN PB1; PROTEIN PB1 F2; PROTEIN PB2; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; VIRUS PROTEIN; VIRUS VECTOR; ANTIVIRUS AGENT;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG RESEARCH; GENE EXPRESSION SYSTEM; GENETIC ENGINEERING; HISTORY OF MEDICINE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVERSE GENETICS; REVIEW; VIRAL GENETICS; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS RESISTANCE; VIRUS TRANSMISSION; VIRUS VIRULENCE; ANTIVIRAL RESISTANCE; GENETICS; HOST RANGE; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A; LYMPHOCYTE; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HOST SPECIFICITY; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LYMPHOCYTES; REVERSE GENETICS;

EID: 84915760598     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/erm.2014.4     Document Type: Review

References (167)

1. WHO(2009) Influenza Seasonal Fact Sheet, No. 211. WHO Media Centre
2. Mao, L., Yang, Y. and Qiu, Y. (2012) Annual economic impacts of seasonal influenza on US counties: spatial heterogeneity and patterns. International Journal of Health Geographics 11, 16
3. Webster, R.G. et al. (1992) Evolution and ecology of influenza A viruses. Microbiological Review 56, 152-179
4. Jagger, B.W. et al. (2012) An overlapping proteincoding region in influenza A virus segment 3 modulates the host response. Science 337, 199-204
5. Bruns, K. et al. (2007) Structural characterization and oligomerization of PB1-F2, a proapoptotic influenza A virus protein. Journal of Biological Chemistry 282, 353-363
6. Portela, A. and Digard, P. (2002) The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. Journal of General Virology 83(Pt 4), 723-734
7. Martin, K. and Helenius, A. (1991) Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import. Cell 67, 117-130
8. Takeda, M. et al. (2002) Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture. Journal of Virology 76, 1391-1399
9. Garcia-Sastre, A. et al. (1998) Influenza A virus lacking the NS1 gene replicates in interferondeficient systems. Virology 252, 324-330
10. Neumann, G., Whitt, M.A. and Kawaoka, Y. (2002) A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned? Journal of General Virology 83(Pt 11), 2635-2662
11. Webby, R.J. et al. (2004) Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 363, 1099-1103
12. Li, S. et al. (1993) Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cellmediated protective immunity against malaria. Proceedings of the National Academy of Sciences USA 90, 5214-5218
13. Sexton, A. et al. (2009) Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. Journal of Virology 83, 7619-7628
14. Taniguchi, T., Palmieri, M. and Weissmann, C. (1978) QB DNA-containing hybrid plasmids giving rise to QB phage formation in the bacterial host. Nature 274, 223-228
15. Palese, P. et al. (1996) Negative-strandRNAviruses: genetic engineering and applications. Proceedings of the National Academy of Sciences USA 93, 11354-11358
16. Parvin, J.D. et al. (1989) Promoter analysis of influenza virus RNA polymerase. Journal of Virology 63, 5142-5152
17. Luytjes, W. et al. (1989) Amplification, expression, and packaging of foreign gene by influenza virus. Cell 59, 1107-1113
18. Schnell, M.J., Mebatsion, T. and Conzelmann, K.K. (1994) Infectious rabies viruses from cloned cDNA. EMBO Journal 13, 4195-4203
19. Bridgen, A. and Elliott, R.M. (1996) Rescue of a segmented negative-strand RNAvirus entirely from cloned complementary DNAs. Proceedings of the National Academy of Sciences USA 93, 15400-15404
20. Neumann, G. et al. (1999) Generation of influenzaA viruses entirely from cloned cDNAs. Proceedings of the National Academy of Sciences USA 96, 9345-9350
21. Zobel, A., Neumann, G. and Hobom, G. (1993) RNA polymerase I catalysed transcription of insert viral cDNA. Nucleic Acids Research 21, 3607-3614
22. Hoffmann, E. et al. (2000) A DNA transfection system for generation of influenza A virus from eight plasmids. Proceedings of the National Academy of Sciences USA 97, 6108-6113
23. Neumann, G. et al. (2005) An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proceedings of the National Academy of Sciences USA 102, 16825-16829
24. Zhang, X. et al. (2009) A one-plasmid system to generate influenza virus in cultured chicken cells for potential use in influenza vaccine. Journal of Virology 83, 9296-9303
25. Skehel, J.J. and Wiley, D.C. (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annual Reviewin Biochemistry 69, 531-569
26. Connor, R.J. et al. (1994) Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 205, 17-23
27. Glaser, L. et al. (2007) Effective replication of human influenza viruses in mice lacking a major alpha2,6 sialyltransferase. Virus Research 126, 9-18
28. Oshansky, C.M. et al. (2011)Avian influenza viruses infect primary human bronchial epithelial cells unconstrained by sialic acid alpha2,3 residues. PLoS One 6, e21183. doi:10.1371/journal.pone.0021183
29. Wilson, I.A. and Cox, N.J. (1990) Structural basis of immune recognition of influenza virus hemagglutinin. Annual Review of Immunology 8, 737-771
30. Schweiger, B., Zadow, I. and Heckler, R. (2002) Antigenic drift and variability of influenza viruses. Medical Microbiology and Immunology 191, 133-138
31. Colman, P.M. et al. (1989) Three-dimensional structures of influenza virus neuraminidaseantibody complexes. Philosophical Transactions of the Royal Soceity of London B - Biological Sciences 323, 511-518
32. Reid, A.H. et al. (1999) Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. Proceedings of the National Academy of Sciences USA 96, 1651-1656
33. Matrosovich, M. et al. (2000) Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. Journal of Virology 74, 8502-8512
34. Korsman, K. (2006) Vaccines. Influenza Report. Flying Publisher, Paris, France
35. Fleming, D.M. (2010) Influenza and influenza vaccines - the need for further developments. European Infectious Disease 4(Suppl. 1), 2-6
36. Cox, R.J., Brokstad, K.A. and Ogra, P. (2004) Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scandinavian Journal of Immunology 59, 1-15
37. Govaert, T.M. et al. (1994) The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. Journal of American Medical Association 272, 1661-1665
38. Corrigan, E.M. and Clancy, R.L. (1999) Is there a role for a mucosal influenza vaccine in the elderly? Drugs Aging 15, 169-181
39. MedImmune Vaccines (2003) Influenza virus vaccine live intranasal - MedImmune vaccines: CAIV-T, influenza vaccine live intranasal. In Drugs R & D (2003/09/04 edn), pp. 312-319
40. Fiore, A.E., Bridges, C.B. and Cox, N.J. (2009) Seasonal influenza vaccines. Current Topics in Microbiology and Immunology 333, 43-82
41. Carter, N.J. and Curran, M.P. (2011) Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 71, 1591-1622
42. Doherty, P.C. and Kelso, A. (2008) Toward a broadly protective influenza vaccine. Journal of Clinical Investigation 118, 3273-3275
43. Du, L., Zhou, Y. and Jiang, S. (2010) Research and development of universal influenza vaccines. Microbes and Infection 12, 280-286
44. Lee, L.Y. et al. (2008) Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. Journal of Clinical Investigation 118, 3478-3490
45. Thomas, P.G. et al. (2006) Cell-mediated protection in influenza infection. Emerging Infectious Diseases 12, 48-54
46. Goodman, A.G. et al. (2011) A human multiepitope recombinant vaccinia virus as a universal Tcellvaccine candidateagainst influenzavirus.PLoS One 6, e25938. doi:10.1371/journal.pone.0025938
47. Booy, R. et al. (2006) Pandemic vaccines: promises and pitfalls. Medical Journal of Australia 185(10 Suppl), S62-S65
48. Subbarao, K. et al. (2003) Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305, 192-200
49. Hatta, M. et al. (2001) Molecular basis for high virulence of Hong Kong H5N1 influenza Aviruses. Science 293, 1840-1842
50. Watanabe, T. et al. (2009) Viral RNA polymerase complex promotes optimal growth of 1918 virus in the lower respiratory tract of ferrets. Proceedings of the National Academy of Sciences USA 106, 588-592
51. Taubenberger, J.K. et al. (2005) Characterization of the 1918 influenza virus polymerase genes. Nature 437, 889-893
52. Subbarao, E.K., London, W. and Murphy, B.R. (1993) A single amino acid in the PB2 gene of influenza A virus is a determinant of host range. Journal of Virology 67, 1761-1764
53. Gabriel, G. et al. (2005) The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host. Proceedings of the National Academy of Sciences USA 102, 18590-18595
54. Shinya, K. et al. (2004) Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine. Journal of Virology 78, 3083-3088
55. Li, Z. et al. (2005) Molecular basis of replication of duck H5N1 influenza viruses in a mammalian mouse model. Journal of Virology 79, 12058-12064
56. de Jong, M.D. et al. (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nature Medicine 12, 1203-1207
57. Detjen, B.M. et al. (1987) The three influenza virus polymerase (P) proteins not associated with viral nucleocapsids in the infected cell are in the form of a complex. Journal of Virology 61, 16-22
58. Pappas, C. et al. (2008) Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proceedings of the National Academy of Sciences USA 105, 3064-3069
59. Chen, W. et al. (2001) A novel influenza A virus mitochondrial protein that induces cell death. Nature Medicine 7, 1306-1312
60. Mazur, I. et al. (2008) The proapoptotic influenza A virus protein PB1-F2 regulates viral polymerase activity by interaction with the PB1 protein. Cellular Microbiology 10, 1140-1152
61. McAuley, J.L. et al. (2007) Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host and Microbe 2, 240-249
62. Conenello, G.M. et al. (2007) A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathogens 3, 1414-1421
63. de la Luna, S. et al. (1995) Influenza virus NS1 protein enhances the rate of translation initiation of viral mRNAs. Journal of Virology 69, 2427-2433
64. Ehrhardt, C. et al. (2007) Influenza A virus NS1 protein activates the PI3 K/Akt pathway to mediate antiapoptotic signaling responses. Journal of Virology 81, 3058-3067
65. Donelan, N.R., Basler, C.F. and Garcia-Sastre, A. (2003) A recombinant influenza Avirus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. Journal of Virology 77, 13257-13266
66. Guo, Z. et al. (2007) NS1 protein of influenzaAvirus inhibits the function of intracytoplasmic pathogen sensor, RIG-I. American Journal of Respiratory Cell and Molecular Biology 36, 263-269
67. Mibayashi, M. et al. (2007) Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza Avirus. Journal of Virology 81, 514-524
68. Opitz, B. et al. (2007) IFNbeta induction by influenza A virus is mediated by RIG-I which is regulated by the viral NS1 protein. Cellular Microbiology 9, 930-938
69. Taubenberger, J.K. (2005) The virulence of the 1918 pandemic influenza virus: unraveling the enigma. Archives of Virology, Supplement (19), 101-115
70. Egorov, A. et al. (1998) Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. Journal of Virology 72, 6437-6441
71. Guan, Y. et al. (2002) Emergence of multiple genotypes ofH5N1avian influenza viruses inHong Kong SAR. Proceedings of the National Academy of Sciences USA 99, 8950-8955
72. Seo, S.H., Hoffmann, E. and Webster, R.G. (2002) Lethal H5N1 influenza viruses escape host antiviral cytokine responses. Nature Medicine 8, 950-954
73. Obenauer, J.C. et al. (2006) Large-scale sequence analysis of avian influenza isolates. Science 311, 1576-1580
74. Sheng, M. and Sala, C. (2001) PDZ domains and the organization of supramolecular complexes. Annual Review in Neuroscience 24, 1-29
75. Jackson, D. et al. (2008) A new influenza virus virulence determinant: the NS1 protein four Cterminal residues modulate pathogenicity. Proceedings of the National Academy of Sciences USA 105, 4381-4386
76. Wang, W. et al. (1999) RNA binding by the novel helical domain of the influenza virus NS1 protein requires its dimer structure and a small number of specific basic amino acids. RNA 5, 195-205
77. Min, J.Y. et al. (2007) A site on the influenza Avirus NS1 protein mediates both inhibition of PKR activation and temporal regulation of viral RNA synthesis. Virology 363, 236-243
78. Hale, B.G. et al. (2008) The multifunctional NS1 protein of influenza A viruses. Journal of General Virology 89(Pt 10), 2359-2376
79. Ayllon, J. et al. (2012) Contribution of NS1 effector domain dimerization to Influenza A virus replication and virulence. Journal of Virology 86, 13095-13098
80. Bottcher, E. et al. (2006) Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. Journal of Virology 80, 9896-9898
81. Horimoto, T. and Kawaoka, Y. (1994) Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. Journal of Virology 68, 3120-3128
82. Wang, M. et al. (2012) Residue Y161 of influenza virus hemagglutinin is involved in viral recognition of sialylated complexes from different hosts. Journal of Virology 86, 4455-4462
83. Glaser, L. et al. (2005) A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. Journal of Virology 79, 11533-11536
84. van Doremalen, N. et al. (2011) A single amino acid in theHAof pH1N1 2009 influenza virus affects cell tropism in human airway epithelium, but not transmission in ferrets. PLoS One 6, e25755. doi:10.1371/journal.pone.0025755
85. de Vries, R.P. et al. (2011) Only two residues are responsible for the dramatic difference in receptor binding between swine and new pandemic H1 hemagglutinin. Journal of Biological Chemistry 286, 5868-5875
86. Schmolke, M. and Garcia-Sastre, A. (2010) Evasion of innate and adaptive immune responses by influenza A virus. Cellular Microbiology 12, 873-880
87. Takeuchi, O. and Akira, S. (2010) Pattern recognition receptors and inflammation. Cell 140, 805-820
88. Le Goffic, R. et al. (2007) Cutting Edge: influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. Journal of Immunology 178, 3368-3372
89. Goodbourn, S., Didcock, L. and Randall, R.E. (2000) Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. Journal of General Virology 81(Pt 10), 2341-2364
90. Lopez, C.B. et al. (2003) Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNAviruses. Journal of Infectious Diseases 187, 1126-1136
91. Fernandez-Sesma, A. et al. (2006) Influenza virus evades innate and adaptive immunity via the NS1 protein. Journal of Virology 80, 6295-6304
92. Haye, K. et al. (2009) The NS1 protein of a human influenza virus inhibits type I interferon production and the induction of antiviral responses in primary human dendritic and respiratory epithelial cells. Journal of Virology 83, 6849-6862
93. Davis, M.M. et al. (1998) Ligand recognition by alpha beta T cell receptors. Annual Review of Immunology 16, 523-544
94. Boon, A.C. et al. (2002) Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. Journal of Virology 76, 2567-2572
95. Goulder, P.J. et al. (2001) Evolution and transmission of stable CTLescape mutations inHIV infection. Nature 412, 334-338
96. Goulder, P.J. et al. (1997) Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Medicine 3, 212-217
97. Yewdell, J.W. and Bennink, J.R. (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annual Review of Immunology 17, 51-88
98. Townsend, A.R. et al. (1986) The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44, 959-968
99. Belz, G.T. et al. (2000) A previously unrecognized H-2D(b)-restricted peptide prominent in the primary influenza A virus-specific CD8(+) T-cell response is much less apparent following secondary challenge. Journal of Virology 74, 3486-3493
100. Sigal, L.J. and Wylie, D.E. (1996) Role of non-anchor residues of Db-restricted peptides in class I binding and TCR triggering. Molecular Immunology 33, 1323-1333
101. Price, G.E. et al. (2000) Viral escape by selection of cytotoxic T cell-resistant variants in influenza A virus pneumonia. Journal of Experimental Medicine 191, 1853-1867
102. Webby, R.J. et al. (2003) Protection and compensation in the influenza virus-specific CD8+ T cell response. Proceedings of the National Academy of Sciences USA100, 7235-7240
103. Andreansky, S.S. et al. (2005) Consequences of immunodominant epitope deletion for minor influenza virus-specific CD8+ -T-cell responses. Journal of Virology 79, 4329-4339
104. La Gruta, N.L. et al. (2006) Avirus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proceedings of the National Academy of Sciences USA 103, 994-999
105. Jenkins, M.R. et al. (2006) Addition of a prominent epitope affects influenzaAvirus-specific CD8+ T cell immunodominance hierarchies when antigen is limiting. Journal of Immunology 177, 2917-2925
106. Kedzierska, K. et al. (2008) Complete modification of TCR specificity and repertoire selection does not perturb a CD8+ T cell immunodominance hierarchy. Proceedings of the National Academy of Sciences USA 105, 19408-19413
107. Florido, M. et al. (2013) Influenza Avirus infection impairs mycobacteria-specific T cell responses and mycobacterial clearance in the lung during pulmonary coinfection. Journal of Immunology 191, 302-311
108. Jegaskanda, S. et al. (2012) Comparison of influenza and SIV specific CD8 T cell responses in macaques. PLoS One 7, e32431. doi:10.1371/ journal.pone.0032431
109. Wojtasiak, M. et al. (2004) Persistent expression of CD94/NKG2 receptors by virus-specific CD8 Tcells is initiated by TCR-mediated signals. International Immunology 16, 1333-1341
110. Reece, J.C. et al. (2010) Timing of immune escape linked to success or failure of vaccination. PLoS One 5, e12774. doi:10.1371/journal.pone.0012774
111. Gerhard,W. et al. (1997) Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunological Reviews 159, 95-103
112. Sealy, R. et al. (2003) Antibody response to influenza infection of mice: different patterns for glycoprotein and nucleocapsid antigens. Immunology 108, 431-439
113. Laursen, N.S. and Wilson, I.A. (2013) Broadly neutralizing antibodies against influenza viruses. Antiviral Res 98, 476-483
114. Kang, S.M., Song, J.M. and Compans, R.W. (2011) Novel vaccines against influenza viruses. Virus Research 162, 31-38
115. Job, E.R. et al. (2013) Addition of glycosylation to influenza A virus hemagglutinin modulates antibody-mediated recognition of H1N1 2009 pandemic viruses. Journal of Immunology 190, 2169-2177
116. Davtyan, H. et al. (2011) The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. Journal of Translational Medicine 9, 127
117. Thomas, P.G. et al. (2006) An unexpected antibody response to an engineered influenza virus modifies CD8+ T cell responses. Proceedings of the National Academy of Sciences USA 103, 2764-2769
118. Snyder, M.H. et al. (1985) Attenuation of wild-type human influenza A virus by acquisition of the PA polymerase and matrix protein genes of influenza A/Ann Arbor/6/60 cold-adapted donor virus. Journal of Clinical Microbiology 22, 719-725
119. Maassab, H.F. and DeBorde, D.C. (1985) Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 3, 355-369
120. Snyder, M.H. et al. (1988) Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. Journal of Virology 62, 488-495
121. Donabedian, A.M. et al. (1988)Amutation in the PA protein gene of cold-adapted B/Ann Arbor/1/66 influenza virus associated with reversion of temperature sensitivity and attenuated virulence. Virology 163, 444-451
122. Restifo, N.P. et al. (1998) Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer. Virology 249, 89-97
123. Zheng, H., Palese, P. and Garcia-Sastre, A. (2000) Antitumor properties of influenza virus vectors. Cancer Research 60, 6972-6976
124. Strobel, I. et al. (2000) Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector. Human Gene Therapy 11, 2207-2218
125. Li, S. et al. (1993) Chimeric influenza virus induces neutralizing antibodies and cytotoxic Tcells against human immunodeficiency virus type 1. Journal of Virology 67, 6659-6666
126. Ferko, B. et al. (1998) Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. Journal of Infectious Diseases 178, 1359-1368
127. Muster, T. et al. (1995) Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. Journal of Virology 69, 6678-6686
128. Gonzalez-Aseguinolaza, G. et al. (2003) Induction of protective immunity against malaria by primingboosting immunization with recombinant coldadapted influenza and modified vaccinia Ankara viruses expressing a CD8 + -T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii. Journal of Virology 77, 11859-11866
129. Gilleland, H.E., Jr. et al. (1997) Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosa. Behring Institute of Mitteilungen 98, 291-301
130. Staczek, J. et al. (1998) A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection. Infection and Immunity 66, 3990-3994
131. McCutchan, F.E. et al. (2000) Diversity of envelope glycoprotein from human immunodeficiency virus type 1 of recent seroconverters in Thailand. AIDS Research and Human Retroviruses 16, 801-805
132. Korber, B. et al. (2001) Evolutionary and immunological implications of contemporary HIV- 1 variation. British Medical Bulletin 58, 19-42
133. Perrin, H. et al. (2010) New approaches to design HIV-1 T-cell vaccines. Current Opinion in HIV and AIDS 5, 368-376
134. Rerks-Ngarm, S. et al. (2009) Vaccination with ALVACand AIDSVAXto prevent HIV-1 infection in Thailand. New England Journal of Medicine 361, 2209-2220
135. Tang, X. and Chen, Z. (2010) The development of an AIDS mucosal vaccine. Viruses 2, 283-297
136. Gherardi, M.M. et al. (2003) Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. Journal of Virology 77, 7048-7057
137. Nakaya, Y. et al. (2004) Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNAvirus vectors. Journal of Virology 78, 9366-9375
138. Goulder, P.J. and Watkins, D.I. (2004) HIV and SIV CTL escape: implications for vaccine design. Nature Reviews Immunology 4, 630-640
139. Pielak, R.M., Schnell, J.R. and Chou, J.J. (2009) Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proceedings of the National Academy of Sciences USA 106, 7379-7384
140. Itzstein, J.C.D.a.M.v. (2001) Anti-influenza virus drug design: sialidase inhibitors. Australian Journal of Chemistry 54, 663-670
141. Hayden, F.G. and de Jong, M.D. (2011) Emerging influenza antiviral resistance threats. Journal of Infectious Diseases 203, 6-10
142. Whitley, R.J. et al. (2013) Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clinical Infectious Disease 56, 1197-1205
143. Yen, H.L. et al. (2013) Resistance to neuraminidase inhibitors conferred by an R292 K mutation in a human influenza virus H7N9 isolate can be masked bya mixed R/K viral population. MBio 4, e00396-13. doi: 10.1128/mBio.00396-13
144. Abed, Y., Goyette, N. and Boivin, G. (2005) Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrobial Agents and Chemotherapy 49, 556-559
145. Abed, Y., Baz, M. and Boivin, G. (2006) Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antiviral Therapy 11, 971-976
146. Pizzorno, A. et al. (2011) Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. Journal of Infectious Diseases 203, 25-31
147. Nelson, M.I. et al. (2009) The origin and global emergence of adamantane resistant A/H3N2 influenza viruses. Virology 388, 270-278
148. Gubareva, L.V. et al. (2001) Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. Journal of Infectious Diseases 183, 523-531
149. Wang, M.Z., Tai, C.Y. and Mendel, D.B. (2002) Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrobial Agents and Chemotherapy 46, 3809-3816
150. Gubareva, L.V. et al. (2010) Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antiviral Therapy 15, 1151-1159
151. Gubareva, L.V. et al. (1996) Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. Journal of Virology 70, 1818-1827
152. Simon, P. et al. (2011) The I222 V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119 Vmutant. Journal of Clinical Microbiology 49, 715-717
153. Manicassamy, B. et al. (2010) Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proceedings of the National Academy of Sciences USA 107, 11531-11536
154. Kittel, C. et al. (2004) Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology 324, 67-73
155. Ku, A.S. and Chan, L.T. (1999) The first case of H5N1 avian influenza infection in a human with complications of adult respiratory distress syndrome and Reye's syndrome. Journal of Paediatrics and Child Health 35, 207-209
156. Fouchier, R.A., Garcia-Sastre, A. and Kawaoka, Y. (2012) Pause on avian flu transmission studies. Nature 481, 443
157. Herfst, S. et al. (2012) Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336, 1534-1541
158. Imai, M. et al. (2012) Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486, 420-428
159. Song, M.S. et al. (2013) Establishment of Vero cell RNA polymerase I-driven reverse genetics for Influenza A virus and its application for pandemic (H1N1) 2009 influenza virus vaccine production. Journal of General Virology 94(Pt 6), 1230-1235
160. Hamamoto, I. et al. (2013) High yield production of influenza virus in Madin Darby canine kidney (MDCK) cells with stable knockdownof IRF7. PLoS One 8, e59892. doi: 10.1371/journal.pone.0059892
161. Fouchier, R.A. et al. (2012) Pause on avian flu transmission research. Science 335, 400-401
162. Fouchier, R.A. et al. (2013) Transmission studies resume for avian flu. Science 339, 520-521
163. Gao, R. et al. (2013) Human infection with a novel avian-origin influenza A (H7N9) virus. New England Journal of Medicine 368, 1888-1897
164. Watanabe, T. et al. (2013) Characterization of H7N9 influenza A viruses isolated from humans. Nature 501, 551-555
165. Tong, S. et al. (2012) A distinct lineage of influenza A virus from bats. Proceedings of the National Academy of Sciences USA 109, 4269-4274
166. Garcia-Sastre, A. (2012) The neuraminidase of bat influenza viruses is not a neuraminidase. Proceedings of the National Academy of Sciences USA 109, 18635-18636
167. Schmid, S., Zony, L.C. and Tenoever, B.R. (2013) A versatile RNA vector for delivery of coding and non-coding RNAs. Journal of Virology 88, 2333-2336